Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the … – Nasdaq
|
Editas Medicine to Present New Data Demonstrating Progress Towards Creating Genome Editing Medicines at the …
Nasdaq As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the … |
